Literature DB >> 33544118

The ERK mitogen-activated protein kinase signaling network: the final frontier in RAS signal transduction.

Jennifer E Klomp1, Jeff A Klomp1,2, Channing J Der1,2.   

Abstract

The RAF-MEK-ERK mitogen-activated protein kinase (MAPK) cascade is aberrantly activated in a diverse set of human cancers and the RASopathy group of genetic developmental disorders. This protein kinase cascade is one of the most intensely studied cellular signaling networks and has been frequently targeted by the pharmaceutical industry, with more than 30 inhibitors either approved or under clinical evaluation. The ERK-MAPK cascade was originally depicted as a serial and linear, unidirectional pathway that relays extracellular signals, such as mitogenic stimuli, through the cytoplasm to the nucleus. However, we now appreciate that this three-tiered protein kinase cascade is a central core of a complex network with dynamic signaling inputs and outputs and autoregulatory loops. Despite our considerable advances in understanding the ERK-MAPK network, the ability of cancer cells to adapt to the inhibition of key nodes reveals a level of complexity that remains to be fully understood. In this review, we summarize important developments in our understanding of the ERK-MAPK network and identify unresolved issues for ongoing and future study.
© 2021 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  PDAC; RAS GTPase; extracellular signal-regulated kinases; mitogen-activated protein kinases

Mesh:

Substances:

Year:  2021        PMID: 33544118     DOI: 10.1042/BST20200507

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  9 in total

1.  Functional and biological heterogeneity of KRASQ61 mutations.

Authors:  Minh V Huynh; G Aaron Hobbs; Antje Schaefer; Mariaelena Pierobon; Leiah M Carey; J Nathaniel Diehl; Jonathan M DeLiberty; Ryan D Thurman; Adelaide R Cooke; Craig M Goodwin; Joshua H Cook; Lin Lin; Andrew M Waters; Naim U Rashid; Emanuel F Petricoin; Sharon L Campbell; Kevin M Haigis; Diane M Simeone; Costas A Lyssiotis; Adrienne D Cox; Channing J Der
Journal:  Sci Signal       Date:  2022-08-09       Impact factor: 9.517

Review 2.  Neurodevelopmental disorders, immunity, and cancer are connected.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  iScience       Date:  2022-05-30

3.  How can same-gene mutations promote both cancer and developmental disorders?

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  Sci Adv       Date:  2022-01-14       Impact factor: 14.136

4.  CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.

Authors:  Jennifer E Klomp; Ye S Lee; Craig M Goodwin; Björn Papke; Jeff A Klomp; Andrew M Waters; Clint A Stalnecker; Jonathan M DeLiberty; Kristina Drizyte-Miller; Runying Yang; J Nathaniel Diehl; Hongwei H Yin; Mariaelena Pierobon; Elisa Baldelli; Meagan B Ryan; Siqi Li; Jackson Peterson; Amber R Smith; James T Neal; Aaron K McCormick; Calvin J Kuo; Christopher M Counter; Emanuel F Petricoin; Adrienne D Cox; Kirsten L Bryant; Channing J Der
Journal:  Cell Rep       Date:  2021-11-30       Impact factor: 9.423

Review 5.  Antibody-Based Approaches to Target Pancreatic Tumours.

Authors:  Marie Sorbara; Pierre Cordelier; Nicolas Bery
Journal:  Antibodies (Basel)       Date:  2022-07-12

Review 6.  Crosstalk between the CBM complex/NF-κB and MAPK/P27 signaling pathways of regulatory T cells contributes to the tumor microenvironment.

Authors:  Tongbing Qi; Ying Luo; Weitong Cui; Yue Zhou; Xuan Ma; Dongming Wang; Xuewen Tian; Qinglu Wang
Journal:  Front Cell Dev Biol       Date:  2022-07-19

Review 7.  Alternative Splicing of MAPKs in the Regulation of Signaling Specificity.

Authors:  Galia Maik-Rachline; Inbal Wortzel; Rony Seger
Journal:  Cells       Date:  2021-12-08       Impact factor: 6.600

8.  Defining RASopathy.

Authors:  Katherine A Rauen
Journal:  Dis Model Mech       Date:  2022-02-01       Impact factor: 5.758

9.  ERK1b, a 46-kDa ERK isoform that is differentially regulated by MEK.

Authors:  Yuval Yung; Zhong Yao; Tamar Hanoch; Rony Seger
Journal:  Cell Biol Int       Date:  2022-04-04       Impact factor: 4.473

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.